Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
NewAmsterdam Pharma Company N.V. - Ordinary Shares
(NQ:
NAMS
)
27.30
-0.25 (-0.91%)
Streaming Delayed Price
Updated: 12:41 PM EDT, Aug 5, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NewAmsterdam Pharma Company N.V. - Ordinary Shares
< Previous
1
2
3
4
5
6
7
Next >
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Today 7:00 EDT
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Host Investor Day on August 5, 2026
July 29, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma and Menarini Group Receive Positive CHMP Opinion Recommending Marketing Authorization for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
July 24, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma (NASDAQ:NAMS) Beats Q1 Revenue and EPS Estimates as Key Trial Catalysts Loom
↗
May 07, 2026
Via
Chartmill
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
July 01, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Upcoming Presentations at the National Lipid Association (NLA) 2026 Scientific Sessions
June 03, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Why This Fund Made a $66 Million Bet on Damora Therapeutics Amid a 700% Surge
↗
May 30, 2026
This clinical-stage biotech develops small molecule therapies for cancer and fibrotic diseases, focusing on galectin-3 and LOXL2 inhibitors.
Via
The Motley Fool
Dyne Stock Is Up 56%. Here's What a $14 Million Stake Reduction Could Mean
↗
May 30, 2026
Dyne Therapeutics targets rare muscle diseases with its FORCE platform, aiming to meet unmet needs in neuromuscular therapeutics.
Via
The Motley Fool
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in June
May 28, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in May
May 11, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Sets PREVAIL Interim Analysis for Q4 2026 on Encouraging Blinded Trends
↗
May 08, 2026
NewAmsterdam Pharma (NASDAQ:NAMS) said it plans to conduct an interim analysis of its ongoing PREVAIL cardiovascular outcomes trial (CVOT) for obicetrapib in the fourth quarter of 2026, citing what...
Via
MarketBeat
NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results
May 07, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session
March 23, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
This Biotech Was Quietly Bought Before a $58 Per Share Takeout
↗
March 21, 2026
This clinical-stage biotech develops oral therapies targeting cancer and inflammatory diseases, with lead candidates in active trials.
Via
The Motley Fool
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 06, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in March
February 25, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
February 18, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 06, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Present at the Guggenheim Emerging Outlook: Biotech Summit
February 04, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities
January 09, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2026
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
NewAmsterdam Pharma to Participate at Upcoming Investor Conferences in December
November 25, 2025
From
NewAmsterdam Pharma N.V.
Via
GlobeNewswire
Investment Powerhouse Backs Biotech Stock to the Tune of $419 Million
↗
November 20, 2025
Bain Capital added more than 12.4 million shares of HeartFlow stock in the thrid quarter
Via
The Motley Fool
Topics
Artificial Intelligence
Regulatory Compliance
Institutional Titan Hits the Jackpot: Biotech Stock Surges by 116% on Buyout Offer
↗
November 20, 2025
Bain Capital's bet on Cidara Therapeutics stocks has paid off in a big way
Via
The Motley Fool
Topics
Regulatory Compliance
Biotech Stock Gets Booted in Latest Fund Update
↗
November 19, 2025
Bain Capital sold its entire stake in Nuvalent stock during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
Portfolio Adjustment: Institutional Heavyweight Exits Biotech Stock
↗
November 19, 2025
Bain Capital completely exited its position in Disc Medicine stock during the third quarter
Via
The Motley Fool
Why Bain Capital Is Selling Shares of This Biotech Stock Now
↗
November 18, 2025
Bain Capital sold $20 million worth of Pharvaris stock during the third quarter.
Via
The Motley Fool
Topics
Regulatory Compliance
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
